Inaticabtagene autoleucel
Phase 2Cell therapy
Inaticabtagene autoleucel is one of 102 biologic programs targeting Systemic Lupus Erythematosus. It is currently in Phase 2.
3
Indications
3
Total Trials
3
Active Trials
101
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
328 competitors in Systemic Lupus Erythematosus
#DrugCompanyPhaseTrials
1Rituxan
RochePhase 3
Olumiant
Eli LillyPhase 3
Stelara
Johnson & JohnsonPhase 3
Rinvoq
AbbViePhase 3
Ocrevus
RochePhase 3
Gazyva
RochePhase 3
Rayos
RRoxane Laboratories
Phase 3
Depo-Provera
Eli LillyPhase 3
Cellcept
NovartisPhase 3
Imuran
LLegacy Health System
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
B-cell acute lymphoblastic leukemia1 trial
Combination of Inaticabtagene Autoleucel With Autologous Hematopoietic Stem Cell Transplantation for Adolescents or Adults With MRD-Positive B-Cell Acute Lymphoblastic Leukemia in Initial Complete Remission.
Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT06608732·20 enrolled
Systemic Lupus Erythematosus1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Inaticabtagene autoleucel. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Cell therapy[2]
- Highest Phase
- Phase 2[1]
- Company
- JJuventas Cell Therapy Ltd.